Seeking Alpha

BioCryst (BCRX +7.5%) is up after terminating its merger agreement with private Presidio...

BioCryst (BCRX +7.5%) is up after terminating its merger agreement with private Presidio Pharmaceuticals, which was contingent on BioCryst securing $60M in financing. However, shares are well off their morning highs. BioCryst had agreed to buy Presidio in an all-stock deal once valued at $101M, but its shares had been cut in more than half since then thanks to a withdrawn application for a hepatitis drug, and the ending of trials for a flu drug. SA's PropThink expects BioCryst to remain on the hunt for fresh capital.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs